A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.

[esophageal squamous cell carcinoma]

Fluoropyrimidine plus platinum (FP )-based chemotherapy has been widely used as a first -line regimen for advanced or recurrent esophageal cancer , and taxanes have shown efficacy after FP-based chemotherapy , but there is no standard regimen for second -line chemotherapy (SLC ). We retrospectively investigated the clinical features of taxane therapy in SLC for esophageal squamous cell carcinoma (ESCC ).The selection criteria were pathologically proven ESCC ; advanced or recurrent disease previously treated with FP at our hospital ; performance status (PS ) 0 -2 ; and adequate organ function . Docetaxel (DTX ) was administered 3 -weekly at 70 mg /m (2 ). Paclitaxel (PTX ) was administered at 100 mg /m (2 ) weekly for 6 weeks , with 1 week 's rest .The analysis covered 163 patients from August 2006 to June 2012 . Median age was 64 years (range 37 -83 : DTX group 132 patients and PTX group 31 ). Progression-free survival and median overall survival (OS ) were 2 .3 and 6 .1 months , respectively , with PTX and 2 .3 and 5 .3 months with DTX . Response rates were 20 .7 % for PTX and 5 .9 % for DTX . The rate of grades 3 -4 neutropenia was higher with DTX (32 .6 %) than with PTX (16 .1 %). Grade 3 febrile neutropenia was seen in 6 .1 % of DTX recipients but in no PTX group . According to multivariate analyses of OS , PS 2 , number of metastatic sites ≧2 , and CRP ≧1 mg /dL were independent predictors of poor prognosis .PTX and DTX were both effective in SLC for ESCC , but their toxicity profiles differed . In terms of febrile neutropenia , PTX seems more appropriate .

Diseases
Validation

Diseases presenting "ptx seems more appropriate" symptom

esophageal squamous cell carcinoma

You can validate or delete this automatically detected symptom